QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM ... - PR Newswire

by Pain management @ Sun, 03 May 2009 02:00:04 -0500
Primary Endpoints Met; Data Demonstrate MoxDuo(TM) IR Provides Better Tolerability Than Morphine and Oxycodone Alone SYDNEY, Australia and BEDMINSTER, N.J., April 20 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX) announced today the ...
  • Recent posts